Drugs / SOTULETINIB
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02829723 | Oct 2016 → Dec 2022 | cancer | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04066244 | Dec 2019 → Feb 2024 | amyotrophic lateral sclerosis | Novartis Pharmaceuticals | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SOTULETINIB | ChEMBL registry synonym — accepted as the source's own label CHEMBL4227505 ↗ |
| Known as | BLZ945 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04066244 ↗ |
| Modality | Small molecule | — CHEMBL4227505 ↗ |
| Route | Oral | “BLZ945 administered orally as a capsule.” NCT02829723 ↗ |